Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke

Terminated

Phase 2 Results

Summary of Purpose

The purpose of this study is to evaluate the safety and tolerability of PF-03049423 following multiple dose administration to subjects with ischemic stroke. The study will also evaluate the efficacy of PF-03049423, relative to placebo, in subjects with ischemic stroke following 90 days of therapy. The study will also... Trial Stopped: See termination reason in detailed description.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 22 January 2016.

1 Dec 2010 22 Sep 2010 1 Dec 2013 1 Dec 2013 1 Jan 2016 19 Feb 2015
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions

Conditions

Sponsors

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment

Contacts

  • Pfizer CT.gov Call Center